# Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

> **NCT01553747** · PHASE3 · COMPLETED · sponsor: **Furiex Pharmaceuticals, Inc** · enrollment: 1146 (actual)

## Conditions studied

- Irritable Bowel Syndrome

## Interventions

- **DRUG:** Eluxadoline
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01553747
- **Lead sponsor:** Furiex Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05-29
- **Primary completion:** 2014-01-09
- **Final completion:** 2014-01-09
- **Target enrollment:** 1146 (ACTUAL)
- **Last updated:** 2018-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01553747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01553747, "Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01553747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*